| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 5% stake in Rezolute, Inc. |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 2.2% stake in Cardiff Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 0.9% stake in Addex Therapeutics Ltd |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 4.4% stake in Xeris Biopharma Holdings, Inc. |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 8.1% stake in Cardiff Oncology, Inc. |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 9% stake in SCYNEXIS, Inc. |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 6% stake in Addex Therapeutics Ltd |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 8.6% stake in Rezolute, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 6.1% stake in Savara Inc. |
| 01/05/2022 |
SC 13D/A
| CAXTON CORP reports a 0% stake in Strongbridge Biopharma plc |
| 01/05/2022 |
SC 13G
| CAXTON CORP reports a 5.7% stake in Xeris Biopharma Holdings, Inc. |
| 03/19/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/14/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/01/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/23/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/22/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| CAXTON CORP reports a 0% stake in Investcorp Credit Management BDC, Inc. |
| 02/03/2020 |
SC 13G
| CAXTON CORP reports a 9.9% stake in Sierra Oncology, Inc. |
| 10/21/2019 |
SC 13G
| CAXTON CORP reports a 5.1% stake in Satsuma Pharmaceuticals, Inc. |
| 07/19/2019 |
SC 13G
| CAXTON CORP reports a 5.3% stake in Sunesis Pharmaceuticals, Inc. |
| 02/14/2019 |
SC 13G/A
| CAXTON CORP reports a 7.5% stake in CM Finance Inc |
|